Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.07 USD | -2.23% | -11.02% | +89.76% |
30/05 | Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating | MT |
07/05 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+89.76% | 30Cr | |
+17.58% | 12TCr | |
+15.22% | 11TCr | |
-6.20% | 2.38TCr | |
+2.39% | 2.24TCr | |
-13.92% | 1.75TCr | |
-11.87% | 1.66TCr | |
-41.64% | 1.64TCr | |
+3.35% | 1.34TCr | |
+25.98% | 1.15TCr |
- Stock Market
- Equities
- ADCT Stock
- News ADC Therapeutics SA
- ADC Therapeutics Plans to End Phase 2 Trial of Zynlonta, Rituximab in Untreated DLBCL Patients